Roche’s Vabysmo to offer ‘fierce competition’ to Regeneron’s Eylea
Summary : Roche’s Vabysmo is having a strong start with doctors, but it has a long way to go if it wants…
Summary : Roche’s Vabysmo is having a strong start with doctors, but it has a long way to go if it wants…
Summary : The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to Gilead Sciences rejecting its New Drug Application…
Summary : This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute…
Summary : The total outlay of the scheme as decided by the government is Rs.6,940 crore. The scheme will provide financial incentives…
SUMMARY: PharmaEssentia Corporation a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in…
Keypoints FDA Approves Low-Dose Tablet for HIV Treatment in Virologically Suppressed Children Weighing at Least 14 kg. Biktarvy Provides an Effective Treatment…
Keypoints USFDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early NSCLC Tecentriq treatment reduced the risk of disease recurrence…